In July of 2026, gynecologic oncologists and members of the Duke Cancer Institute (DCI) Andrew Berchuck, MD, and Haley Moss, MD, MBA (pictured), announced the launch of the Duke Hereditary Gynecologic Cancer Program. The program serves women with inherited genetic mutations that substantially increase the risk of ovarian and uterine cancers.
Drs. Berchuck and Moss, both of whom have extensive specialized training, expertise and experience in cancer genetics, lead the program. They work closely with the genetic counselors in the DCI Clinical Cancer Genetics Program. The focus is to prevent gynecologic cancer deaths in high-risk women who carry mutations related to BRCA1/BRCA2, Lynch Syndrome and other genes. This involves personalized approaches that may include screening and early detection, and prophylactic removal of the ovaries, fallopian tubes and/or uterus, while accounting for fertility concerns and issues related to menopause.
Drs. Berchuck and Moss work in collaboration with colleagues in breast surgery, gastroenterology and reproductive endocrinology to address all aspects of hereditary cancer risk.